3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Other hematologic neoplasm
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
35
Rituximab
33
venetoclax
24
ibrutinib
14
Vincristine
14
Prednisone
14
Doxorubicin
14
Gemcitabine
13
pembrolizumab
12
fludarabine
12
Bendamustine Hydrochloride
11
Etoposide
10
obinutuzumab
9
Filgrastim
9
Dexamethasone
9
Bortezomib
9
fludarabine phosphate
8
Mycophenolic Acid
8
Drug Therapy
8
ofatumumab
7
Whole-Body Irradiation
7
Sirolimus
7
Peripheral Blood Stem Cell Transplantation
7
Methotrexate
7
Busulfan
7
Therapeutics
6
Radiotherapy
6
Mesna
6
Lenalidomide
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
capmatinib
×
Lymphoid
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled